CAMBRIDGE, Mass.--(BUSINESS WIRE)--ImmusanT, Inc., a company developing Nexvax2®, a therapeutic vaccine designed to protect against the effects of gluten exposure in HLA-DQ2.5+ patients with celiac ...
NEWARK, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients ...
SUFFERN, NY--(Marketwired - May 11, 2015) - CDx Diagnostics today announced that three studies examining the WATS 3D biopsy will be presented at Digestive Disease Week 2015 (DDW), taking place from ...
SAN DIEGO--(BUSINESS WIRE)-- Santarus, Inc. (NAS: SNTS) today announced that additional data from two pivotal clinical studies with UCERIS ® (budesonide) extended release tablets will be featured in ...
Poster #Su1298: Neff et al. "Improved Outcomes in Hepatic Encephalopathy Using Rifaximin Monotherapy Compared to Rifaximin and Lactulose Combination Therapy" Poster #1300: Neff et al. "Efficacy and ...
WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...
Lucid and collaborators will present data on three studies on EsoGuard® esophageal precancer testing and one on a new genetic classifier of esophageal neoplasia NEW YORK, March 20, 2024 ...
Santarus Announces UCERIS (budesonide) Poster Presentations at Digestive Disease Week Meeting SAN DIEGO--(BUSINESS WIRE)-- Santarus, Inc. (NAS: SNTS) today announced that additional data from two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback